The therapy of endometrioisis. New prospects;La terapia dell'endometriosi. Nuove prospettive

Minerva Ginecologica

Volumn 55, Issue 1, 2003, Pages 15-23

  Somigliana, E ^a,b   Chiodini, A ^a   Odorizzi, M P ^a   Pompei, F ^a   Vigano P ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b II Clinica Ostetrico Ginecologica   (Italy)

^c NONE

Author keywords

Aromatase; Cell adhesion; Endometriosis; Enzyme inhibitors; Immune system; Raloxifene; Therapy

Indexed keywords

ANTIINFLAMMATORY AGENT; AROMATASE INHIBITOR; ESTROGEN; IMMUNOMODULATING AGENT; RALOXIFENE;

ADHESION; DISEASE ASSOCIATION; ENDOMETRIOSIS; HUMAN; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; IMPLANT; INTERMETHOD COMPARISON; RECURRENT DISEASE; REVIEW; SURGICAL TECHNIQUE; SYMPTOMATOLOGY; TREATMENT OUTCOME; TREATMENT PLANNING;

ADHESIONS; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTI-INFLAMMATORY AGENTS; AROMATASE INHIBITORS; CLINICAL TRIALS; DRUG EVALUATION, PRECLINICAL; ENDOMETRIOSIS; ENZYME INHIBITORS; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PAPIO; PREGNANCY; PREGNANCY RATE; RALOXIFENE; RATS; RECURRENCE; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 0037318583     PISSN: 00264784     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Marcoux S, Maheux R, Bèrubè S. Laparoscopic surgery in infertile women with minimal or mild endometriosis. N Engl J Med 1997;337:217-22.
2. Sutton C, Ewen S, Whitelow N. Prospective, randomized, double-blind controlled trial of laser laparoscopy in the treatment of pelvic pain associated with minimal, mild, and moderate endometriosis. Fertil Steril 1994;62:696-700.
3. Sutton C, Pooley A, Ewen S. Follow-up report on a randomized controlled trial of laser laparoscopy in the treatment of pelvic pain associated with minimal to moderate endometriosis. Fertil Steril 1997;68:1070-4.
4. Vercellini P, Cortesi I, Crosignani PG. Progestins for symptomatic endometriosis: a critical analysis of the evidence. Fertil Steril 1997;68:393-401.
5. Vercellini P, De Giorgi O, Pesole A, Zaina B, Pisacreta A, Crosignani PG. Prevention of recurrences by postoperative medical treatment. In: Lemay A, Maheux R, editors. Understanding and managing endometriosis. Advances in research and practice. Quebec City: Parthenon Publishing; 1998.p.261-8.
6. Bianchi S, Busacca M, Agnoli B, Candiani M, Calia C, Vignali M. Effects of 3 month therapy with danazol after laparoscopic surgery for stage III/IV endometriosis: a randomized study. Hum Reprod 1999;14:1335-7.
7. Busacca M, Somigliana E, Bianchi S, De Marinis S, Calia C, Candiani M. Postoperative GnRH analogue treatment after conservative surgery for symptomatic endometriosis stage III-IV: a randomized controlled trial. Hum Reprod 2001;16:2399-402.
8. Buzdar AV. Role of aromatase inhibitors in advanced breast cancer. Endocr Relat Cancer 1999;6:219-25.
9. Bulun SE, Zeitoun KM, Takayama K, Noble L, Michael D, Simpson E et al. Aromatase expression in endometriosis: biology and clinical perspectives. In: Lemay A and Maheux R, editors. Understanding and managing endometriosis. Advances in research and practice. Quebec City: Parthenon Publishing; 1998.p.139-48.
10. Zeitoun KM, Bulun SE. Aromatase: a key molecule in the pathophysiology of endometriosis and a therapeutic target. Fertil Steril 1999;72:961-9.
11. Bulun SE, Zeitoun KM, Takayama K, Sasano H. Molecular basis for treating endometriosis with aromatase inhibitors. Hum Reprod Update 2000;6:413-8.
12. Kudoh M, Susaki Y, Ideyama Y, Nanya T, Mori M, Shikama H. Inhibitory effects of a novel aromatase inhibitor, YM511, on growth of endometrial explants and insuline-like growth factors-I gene expression in rats with experimental endometriosis. J Steroid Biochem Molec Biol 1997;63:75-80.
13. Yano S, Ikegami Y, Nakao K. Studies on the effect of the new non-steroidal aromatase inhibitor fadrazole hydrochloride in an endometriosis model in rats. Arzneimittelforschung 1996;46:192-5.
14. Santen R, Harvey H. Use of aromatase inhibitors in breast carcinoma. End Relat Cancer 1999;6:75-92.
15. Buelke-Sam J, Bryant HU, Francis PC. The selective estrogen receptor modulator, raloxifene: an overview of nonclinical pharmacology and reproductive and developmental testing. Reprod Toxicol 1998;12:217-21.
16. Dhingra K. Selective estrogen receptor modulation: the search for an ideal hormonal therapy for breast cancer. Cancer Invest 2001;19:649-59.
17. Swisher DK, Tague RM, Seyler DE. Effect of the selective estrogen receptor modulator raloxifene on explanted uterine growth in rats. Drug Dev Res 1995;36:43-5.
18. Fanning P, Kuehl T, Lee R, Pearson S, Wincek T, Pliego J et al. Video mapping to assess efficacy of an antiestrogen (raloxifene) on spontaneous endometriosis in the rhesus monkey, macaca mulata. In: Kuehl TJ, editor. Bunkley day proceeding. Temple (TX): Texas A&M University Health Science Centre; 1995.p.51-61.
19. Baker VL, Draper M, Paul S, Allerheiligen S, Glant M, Shifren J et al. Reproductive endocrine and endometrial effects of raloxifene hydrochloride, a selective estrogen receptor modulator, in women with regular menstrual cycles. J Clin Endocrinol Metab 1998;83:6-13.
20. Braun DP, Dmowski WP. Endometriosis: abnormal endometrium and dysfunctional immune response. Curr Opin Obstet Gynecol 1998;10:365-69.
21. Somigliana E, Viganó P, Vignali M. Endometriosis and unexplained recurrent spontaneous abortion: pathological states resulting from aberrant modulation of natural killer cell functin? Hum Reprod 1999;5:41-52.
22. Kupker W, Schultze-Mosgau A, Diedrich K. Paracrine changes in the peritoneal environment of women with endometriosis. Hum Reprod Update 1998;4:719-23.
23. Sharpe-Timms KL. Basic research in endometriosis. Obstet Gynecol Clin North Am 1997;24:269-90.
24. Ho H-N, Wu M-Y, Yang Y-S. Peritoneal cell immunity and endometriosis. Am J Reprod Immunol 1997;38:400-12.
25. Lebovic DI, Mueller M, Taylor RN. Immunobiology of endometriosis. Fertil Steril 2001;75:1-10.
26. Somigliana E, Viganó P, Rossi G, Carinelli S, Vignali M, Panina-Bordignon P. Endometrial ability to implant in ectopic sites can be prevented by interleukin-12 in a murine model of endometriosis. Hum Reprod 1999;14:2944-50.
27. Ingelmo JMR, Quereda F, Acièn P. Intraperitoneal and subcutaneous treatment of experimental endometriosis with recombinant human interferon-α-2b in a murin model. Fertil Steril 1999;71:907-11.
28. Keenan JA, Williams-Boyce PK, Massey PJ, Chen TT, Caudle MR, Bukovsky A. Regression of endometrial explants in a rat model of endometriosis treated with the immune modulators loxoribine and levamisole. Fertil Steril 1999;72:135-41.
29. Ali AFM, Fateen B, Ezzet A, Badawy H, Ramadan A, El-Tobge A. Laparoscopic intraperitoneal injection of human interferon-α-2b in the treatment of pelvic endometriosis: a new modality. Obstet Gynecol 2000;95(Suppl.):478-9.
30. Nothnick WB. Treating endometriosis as an autoimmune disease. Fertil Steril 2001;76:223-31.
31. Steinleitner A, Lambert H, Roy S. Immunomodu-lation with pentoxifylline abrogates macrophage-mediated infertility in an in vivo model: a paradigm for a novel approach to the treatment of endometriosis-associated subfertility. Fertil Steril 1991;55:26-31.
32. Nothnick WB, Curry TE, Vernon MW. Immunomo-dulation of rat endometriotic implant growth and protein production. Am J Reprod Immunol 1994;31:151-62.
33. Balasch J, Creus M, Fàbregues F, Carmona F, Martinez-Romàn S, Manau D et al. Pentoxifylline versus placebo in the treatment of infertility associated with minimal or mild endometriosis: a pilot study randomized clinical trial. Hum Reprod 1997;12:2046-50.
34. D'antonio M, Martelli F, Peano S, Papoian R, Borrelli F. Ability of recombinant human TNF binding protein-1 (r-hTBP-1) to inhibit the development of experimentally-induced endometriosis in rats. J Reprod Immunol 2000;48:81-98.
35. D'Hooghe TM, Cuneo S, Nugent N, Chai D, Deer F, Mwenda J. Recombinant human TNF binding protein-1 (r-hTBP-1) inhibits the development of endometriosis in baboons: a prospective, randomized, placebo- and drug-controlled study. Fertil Steril 2001;76:S1.
36. Jansen RP. Early laparoscopy after pelvic operations to prevent adhesions: safety and efficacy. Fertil Steril 1988;49:26-31.
37. Damario MA, Rock JA. Methods to prevent post-operative adhesion formation in gynecologic surgery. J Gynecol Technol 1995;1:77-88.
38. Perez RJ. Second-look laparoscopy adhesiolysis. The procedure of choice for preventing adhesion recurrence. J Reprod Med 1991;36:700-2.
39. Spietvogel K, Shwayder J, Coddincton CC. Surgical management of adhesions, and tubal pathology in the woman with infertility. Clin Obstet Gynecol 2000;43:916-28.
40. Di Zerega GS, Verco SJS, Young P, Kettel M, Kobak W, Martin D et al. A randomized, cotrolled pilot study of the safety and efficacy of 4% icodextrin solution in the reduction of adhesions following lapariscopic gynaecological surgery. Hum Reprod 2002;17:1031-8.
41. Watson A, Vandekerckhove P, Lilford R. Liquid and fluid agents for preventing adhesions after surgery for subfertility. Cochrane Database Syst Rev 2000;3:CD001298
42. Farquhar C, Vandekerckhove P, Watson A, Vail A, Wiseman D. Barrier agents for preventing adhesions after surgery for subfertility. Cochrane Database Syst Rev 2000;2:CD000475.
43. Wright JA, Sharpe-Timms KL. Gonadotropin-releasing hormone agonist therapy reduces postoperative adhesion formation and reformation after adhesiolysis in rat models for adhesion formation and endometriosis. Fertil Steril 1995;63:1094-100.
44. Mais V, Ajossa S, Marongiu D, Pairetti RF, Guerriero S, Melis GB. Reduction of adhesion reformation after laparoscopic endometriosis surgery: a randomized trial with an oxidized regenerated cellulose absorbable barrier. Obstet Gynecol 1995;86:512-5.
45. Sekiba K. Use of Interceed (TC7) absorbable adhesion barrier to reduce postoperative adhesion reformation in infertility and endometriosis surgery. The Obstetrics and Gynecology Adhesion Prevention Committee. Obstet Gynecol 1992;79:518-22.